Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-05-04

Clinical Trial Update: CEP-701 for PH-negative Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of CEP-701 (lestaurtinib) for PH-negative myelofibrosis completed, with results posted in May 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CEP-701 (lestaurtinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Myelofibrosis | Phase 2 | Status: COMPLETED | Results posted: 2011-05-04